Key result
Selective serotonin reuptake inhibitor exposure in older patients with major depression was associated with an increased risk of attempted suicide compared to no treatment.
Why the study?
Does treatment with selective serotonin reuptake inhibitors increase the risk of suicidality or suicide in older people with major depression?
Systematic Review (n=1,281)
Does treatment with selective serotonin reuptake inhibitors increase the risk of suicidality or suicide in older people with major depression?
SSRI treatment in older people with major depression may be associated with an increased risk of suicide attempts and completed suicide over long-term follow-up compared to no treatment, highlighting the need for regular monitoring.
Answers are grounded in this paper and cite their sources.
Supports enhanced suicidality monitoring in older SSRI users; extends meta-analytic evidence on long-term risks.
Background Suicide among the elderly is an emerging public health issue. In Australia, suicide is a leading cause of death, most notably amongst elderly men over the age of 75. Depression is one of the main causes of suicide in older people. Selective serotonin reuptake inhibitors are considered to be a safe pharmacological therapy in the management of depression in adults. The risk of suicidality/suicide associated with the use of antidepressants in older people is unclear. Objectives The objective of this review was to determine the association between treatment with selective serotonin reuptake inhibitors and suicidality/suicide in older people who suffer from major depression. Inclusion criteria Types of participants Consideration was given to studies that included older people aged 60 years and over, regardless of gender or ethnic background, with Diagnostic and Statistical Manual of Mental Disorders Fourth Edition or equivalent diagnostic criteria for Major Depressive Disorder without psychotic features. Types of intervention(s)/phenomena of interest The review considered treatments using any selective serotonin reuptake inhibitors medication. Comparators included placebo or a different class of antidepressants including monoamine oxidase inhibitors or tricyclic antidepressants. Types of studies This review considered both experimental and observational study designs including randomized controlled trials, non-randomized controlled trials, prospective and retrospective cohort studies and case control studies. Types of outcomes The primary outcome measures of interest in this systematic review were worsening or emergent suicidal ideation, attempted suicide and completed suicide. For this systematic review, the term ‘suicide attempt’ referred to potentially self-injurious behavior with a non-fatal outcome. Search strategy A three-step search strategy was employed that aimed to locate both published and unpublished studies in the English language. An initial search in PubMed was followed by a second search using all identified keywords and index terms across multiple databases and grey literature sites. Finally, the reference list of all identified reports and articles were searched for additional studies. Methodological quality Critical appraisal was undertaken by two independent reviewers using the standard critical appraisal instrument from the Joanna Briggs Institute Mata-Analysis of Statistical Assessment and Review Instrument. The McMaster Quality Assessment Scale for Harms was used to analyse reporting quality on suicide related harm. Data collection The primary data on the number of emergent or worsening of suicidal ideation, attempted suicide and completed suicides, in both arms of randomized controlled trials and observational studies was extracted using the standardized data extraction tool from the Joanna Briggs Institute Mata-Analysis of Statistical Assessment and Review Instrument. Baseline demographic data on each study was collected for presentation in tabular format. Data synthesis The data from randomized controlled trials and observational studies was pooled separately in statistical meta-analysis using RevMan V 5.1 software (The Cochrane Collaboration). Population demographic and other study characteristics were presented in tables and as a narrative summary. Results Following critical appraisal, eight randomized controlled trials and five observational studies (i.e. population cohort and retrospective case control studies) with data on suicide-related events were included in the systematic review. Based on the data on from two randomized controlled trials involving a total of 1281 older people treated with selective serotonin reuptake inhibitors compared to placebo, the OR for the risk of emergent suicidal ideation was 0.52 (95% CI 0.14-1.94) Chi2 =0.19, I2 =0. There was no difference in the risk of suicide attempt between older depressed people treated with selective serotonin reuptake inhibitors compared to other antidepressants with OR=1.0 (95% CI0.14-7.10) Chi2 =3.88, I2 =23%. Chi2 results indicated non-significant heterogeneity among the experimental studies. In terms of completed suicide, meta-analysis of two observational studies of seven to 11 years of selective serotonin reuptake inhibitor exposure, the risk ratio (RR) was 1.06 (95% CI 0.68-1.66) Chi2 =34.81, I2 =94%. In a meta-analysis of three observational studies of 2-11 years of selective serotonin reuptake inhibitor exposure, the RR for attempted suicide was 1.18 (95% CI 1.10-1.27) Chi2 =14.75, I2 =93% in selective serotonin reuptake inhibitor exposed elderly patients compared to no treatment group. The results of Chi2 tests indicated presence of significant heterogeneity among the included observational studies. Conclusions This study found some evidence that suggests increased risk of suicide attempt and suicide in older people with major depression who are on selective serotonin reuptake inhibitor treatment over two to 11 years compared to no treatment. Despite the presence of heterogeneity, the findings of this review raise important clinical implications such as the need to monitor suicide risk regularly in this vulnerable population. Implications for research The quality of clinical trials may be improved by including both active and passive surveillance using clinical and research rating scales to accurately assess risk of suicide in all clinical trials involving antidepressants and other psychotropic medications. Implications for practice Routine assessment of suicide risk is highly recommended prior to the commencement, change in dose or cessation of selective serotonin reuptake inhibitors treatment in the elderly and youth alike in daily clinical practice. In older people, the need for longer term maintenance selective serotonin reuptake inhibitors treatment must be clearly justified and the risk of suicide is regularly monitored.
No takes yet. Share an insight, caveat, or question.
KoKoAung et al. (2015) conducted a systematic review in Major depression (n=1,281). Selective serotonin reuptake inhibitors vs. Placebo, other antidepressants, or no treatment was evaluated on Attempted suicide (RR 1.18, 95% CI 1.10-1.27). Selective serotonin reuptake inhibitor exposure in older patients with major depression was associated with an increased risk of attempted suicide compared to no treatment.
Synapse has enriched 10 related papers. Consider them for comparative context: